Patents by Inventor Michal Chodynski
Michal Chodynski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150031898Abstract: A convergent synthesis of the prostaglandin F2? analogues, travoprost and bimatoprost, was developed employing Julia-Lythgoe olefination of the structurally advanced phenylsulfone with an enantiomerically pure aldehyde ?-chain synthon. The novel convergent strategy allows the synthesis of a whole series of prostaglandin analogues of high purity from a common and structurally advanced prostaglandin intermediate.Type: ApplicationFiled: March 8, 2013Publication date: January 29, 2015Applicant: INSTYTUT FARMACEUTYCZNYInventors: Iwona Dams, Andrzej Kutner, Michal Chodynski, Malgorzata Krupa, Anita Pietraszek, Marta Zezula, Piotr Cmoch, Monika Kosinska
-
Publication number: 20130006003Abstract: The present invention discloses the synthone of Formula (I), wherein R1 and R2 are the same or different and represent independently hydrogen atom or hydroxyl protecting group, and its use for preparation of 19-nor vitamin D derivatives of general Formula (IV), wherein represents single or double bond, p represents an integer 0 to 3, R1 and R2 represent independently hydrogen atom or hydroxyl protecting group, R3 represents hydrogen atom, CH3 or hydroxyl group, R4, R5 and R6 represent independently hydrogen atom, C1-C3-alkyl or hydroxyl group or two of R4, R5 and R6 substituents altogether form cyclopropyl group, in particular for preparation of paricalcitol.Type: ApplicationFiled: August 7, 2010Publication date: January 3, 2013Applicant: INSTYTUT FARMACEUTYCZNYInventors: Michal Chodynski, Malgorzata Krupa, Krzysztof Krajewski, Marek Kubiszewski, Andrzej Kutner, Anita Pietraszek, Kinga Trzcinska
-
Publication number: 20120101057Abstract: The invention relates to a combined therapy, wherein addition of a vitamin D analogue to the standard treatment regimen based on cytostatics, 5-fluorouracil and/or its precursors, generates potential possibility of achieving beneficial therapeutic effect in the first-line chemotherapy or adjuvant therapy of colorectal carcinoma. Vitamin D analogues are selected from a group consisting of tacalcitol, calcipotriol and 5,6-trans-isomer of calcipotriol.Type: ApplicationFiled: June 9, 2010Publication date: April 26, 2012Applicant: INSTYTUT FARMACEUTYCZNYInventors: Joanna Wietrzyk, Magdalena Milczarek, Andrzej Kutner, Michal Chodynski
-
Patent number: 7915241Abstract: Disclosed is a process for the preparation of 24-alkyl analogs of cholecalcyferol of Formula 1 having a (5E) or (5Z) configuration, wherein X represents a hydrogen atom, a hydroxy group or an OR1 group, where R1, R2 and R3 may be the same or different and represent groups suitable for hydroxyl protection, and R4 is a C1-6 alkyl chain or a C1-6 cykloalkyl group, optionally substituted with C1-3 alkyl groups, especially for calcipotriol. The invention also provides new intermediates and non-racemic compounds being valuable synthones for the synthesis of pharmacologically active substances.Type: GrantFiled: October 8, 2004Date of Patent: March 29, 2011Assignee: Instytut FarmaceutycznyInventors: Andrzej Kutner, Jacek Martynow, Michal Chodynski, Wieslaw Szelejewski, Hanna Fitek, Malgorzata Krupa
-
Patent number: 7829746Abstract: A process for the preparation of calcipotriol at least including: (a) reacting a C-22 phenylsulfonyl derivative of cholecalciferol of Formula 2, wherein R1 and R2 are the same or different and represent hydroxyl protecting groups, with a silyl derivative of alfa-hydroxy aldehyde of Formula 3, wherein R3 represents silyl group of formula Si(R4)(R5)(R6), where R4-R6 are the same or different and represent C1-6 alkyl or phenyl groups, in the presence of a strong organic base in an aprotic solvent, followed by reductive desulfonation of the obtained diastereomeric mixture of alfa-hydroxysulfones with sodium amalgam, removal of the hydroxyl protecting groups, and purification of the product. The process leads to the formation of calcipotriol containing less than 0.3% of the (22Z)-isomer. The obtained calcipotriol is free of mercury traces.Type: GrantFiled: January 11, 2010Date of Patent: November 9, 2010Assignee: Instytut FarmaceutycznyInventors: Andrzej Kutner, Michal Chodynski, Kinga Leszczynska, Wieslaw Szelejewski, Hanna Fitak
-
Publication number: 20100222614Abstract: A process for the preparation of calcipotriol at least including: (a) reacting a C-22 phenylsulfonyl derivative of cholecalciferol of Formula 2, wherein R1 and R2 are the same or different and represent hydroxyl protecting groups, with a silyl derivative of alfa-hydroxy aldehyde of Formula 3, wherein R3 represents silyl group of formula Si(R4)(R5)(R6), where R4-R6 are the same or different and represent C1-6 alkyl or phenyl groups, in the presence of a strong organic base in an aprotic solvent, followed by reductive desulfonation of the obtained diastereomeric mixture of alfa-hydroxysulfones with sodium amalgam, removal of the hydroxyl protecting groups, and purification of the product. The process leads to the formation of calcipotriol containing less than 0.3% of the (22Z)-isomer. The obtained calcipotriol is free of mercury traces.Type: ApplicationFiled: January 11, 2010Publication date: September 2, 2010Applicant: INSTYTUT FARMACEUTYCZNYInventors: Andrzej KUTNER, Michal CHODYNSKI, Kinga LESZCZYNSKA, Wieslaw SZELEJEWSKI, Hanna FITAK
-
Publication number: 20080255380Abstract: Preparation of sulfonyl derivatives of cholecalciferol of Formula 1, wherein R1 is a protective group, preferably a t-butyl(dimethyl)silyl, and R2 is a heterocyclic group, such as a 2-thiazolyl, a 2-benzothiazolyl, a 1-phenyl-1H-tetrazo-5-yl, a 2-pyridyl, a 2-pyrimidynyl, a 1-isochinolinyl, a 1-methyl-2-imidazyl, or a 4-alkyl-1,2,4-triazo-3-yl, comprises the conversion of the hydroxyl derivative of cholecalciferol into the corresponding sulfide followed by its oxidation to the respective sulfone characterized by the use of a hydroxyl derivative of cholecalciferol as a starting material, in which the triene system is protected as a Diels-Alder adduct, and in particular as an adduct with sulfur dioxide of the Formula 2a. Novel are also the derivatives of Formula 3a and 4a, isolated in the process provided by the invention.Type: ApplicationFiled: May 13, 2005Publication date: October 16, 2008Applicant: INSTYTUT FARMACEUTYCZNYInventors: Michal Chodynski, Malgorzata Krupa, Hanna Fitak, Jerzy Winiarski, Teresa Ryznar, Bartlomiej Gorecki, Wieslaw Szelejewski, Andrzej Kutner
-
Publication number: 20080214876Abstract: A process for the preparation of a pharmaceutical-grade anhydrous calcipotriol comprising: (a) dissolving crude calcipotriol having a water content of X % by weight in a first solvent or in a mixture of two or more first solvents, said first solvent or said mixture of two or more first solvents forming an azeotropic system with water, to obtain a solution of crude calcipotriol; (b) obtaining an intermediate calcipotriol by (i) placing said solution of crude calcipotriol under a reduced pressure and evaporating, if X is greater than or equal to 1, or (ii) crystallizing, if X is lower than 1; and (c) re-dissolving said intermediate calcipotriol in a second solvent or a mixture of two or more second solvents, said second solvent being anhydrous, and crystallizing at least once to obtain pharmaceutical-grade anhydrous calcipotriol.Type: ApplicationFiled: December 29, 2005Publication date: September 4, 2008Applicant: INSTYTUT FARMACEUTYCZNYInventors: Andrzej Kutner, Michal Chodynski, Teresa Ryznar, Hanna Fitak, Jerzy Winiarski, Bartlomiej Gorecki, Agnieszka Burzynska, Wieslaw Szelejewski
-
Publication number: 20050119241Abstract: Disclosed is a process for the preparation of 24-alkyl analogs of cholecalcyferol of Formula 1 having a (5E) or (5Z) configuration, wherein X represents a hydrogen atom, a hydroxy group or an OR1 group, where R1, R2 and R3 may be the same or different and represent groups suitable for hydroxyl protection, and R4 is a C1-6 alkyl chain or a C1-6 cykloalkyl group, optionally substituted with C1-3 alkyl groups, especially for calcipotriol. The invention also provides new intermediates and non-racemic compounds being valuable synthones for the synthesis of pharmacologically active substances.Type: ApplicationFiled: October 8, 2004Publication date: June 2, 2005Applicant: Instytut FarmaceutycznyInventors: Andrzej Kutner, Jacek Martynow, Michal Chodynski, Wieslaw Szelejewski, Hanna Fitak, Malgorzata Krupa